{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:01:08Z","timestamp":1790737268240,"version":"4.1.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T00:00:00Z","timestamp":1644278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008732","name":"Uehara Memorial Foundation","doi-asserted-by":"publisher","award":["202040073"],"award-info":[{"award-number":["202040073"]}],"id":[{"id":"10.13039\/100008732","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>X-linked Alport syndrome (XLAS) is caused by pathogenic variants in <jats:italic>COL4A5<\/jats:italic> and is characterized by progressive kidney disease, hearing loss, and ocular abnormalities. Recent advances in genetic analysis and further understanding of genotype-phenotype correlations in affected male patients raises the importance of detecting splicing variants in <jats:italic>COL4A5<\/jats:italic>. Aberrant splicing of <jats:italic>COL4A5<\/jats:italic> is caused not only by canonical splice site variants but also non-canonical splice site variants such as deep intronic changes or even substitutions in exons. Patients with splicing variants account for ~15% of all cases in XLAS. In addition, it has been shown that there is a significant difference in kidney survival depending on the aberrant splicing patterns of transcripts- in particular in-frame or out-of-frame nucleotide changes in transcripts. Therefore, cDNA analysis of patient mRNA is necessary to determine the impact of splice site variants and to confirm a diagnosis of XLAS and to predict the kidney prognosis. However, it is usually difficult to amplify <jats:italic>COL4A5<\/jats:italic> transcripts extracted from peripheral blood leukocytes. For these cases, <jats:italic>in vitro<\/jats:italic> minigene assays or RNA sequence extracted from urine derived cells can confirm aberrant splicing patterns. Moreover, controlling aberrant splicing by nucleic acids or small molecular compounds in genetic diseases are attracting attention as a potential therapeutic strategy. Here, we review the frequency of splicing variants in <jats:italic>COL4A5<\/jats:italic>, the latest diagnostic strategies, and the prospects for new therapeutic approaches.<\/jats:p>","DOI":"10.3389\/fmed.2022.841391","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T08:07:24Z","timestamp":1644307644000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":33,"title":["The Contribution of COL4A5 Splicing Variants to the Pathogenesis of X-Linked Alport Syndrome"],"prefix":"10.3389","volume":"9","author":[{"given":"Tomohiko","family":"Yamamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Horinouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Aoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Lennon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kandai","family":"Nozu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1136\/bmj.1.3454.504","article-title":"Hereditary familial congenital haemorrhagic nephritis","volume":"1","author":"Alport","year":"1927","journal-title":"Br Med J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1681\/ASN.V991736","article-title":"Alport syndrome and thin glomerular basement membrane disease","volume":"9","author":"Kashtan","year":"1998","journal-title":"J Am Soc Nephrol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/ki.1996.459","article-title":"Alport syndrome","volume":"50","author":"Kashtan","year":"1996","journal-title":"Kidney Int."},{"key":"B4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s10157-018-1629-4","article-title":"A review of clinical characteristics and genetic backgrounds in Alport syndrome","volume":"23","author":"Nozu","year":"2019","journal-title":"Clin Exp Nephrol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/00005792-199909000-00005","article-title":"Alport syndrome. An inherited disorder of renal, ocular, and cochlear basement membranes","volume":"78","author":"Kashtan","year":"1999","journal-title":"Medicine"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e883","DOI":"10.1002\/mgg3.883","article-title":"Comparison between conventional and comprehensive sequencing approaches for genetic diagnosis of Alport syndrome","volume":"7","author":"Yamamura","year":"2019","journal-title":"Mol Genet Genomic Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1681\/ASN.V114649","article-title":"X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males","volume":"11","author":"Jais","year":"2000","journal-title":"J Am Soc Nephrol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1681\/ASN.2009070784","article-title":"Genotype-phenotype correlation in X-linked Alport syndrome","volume":"21","author":"Bekheirnia","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1093\/ndt\/17.7.1218","article-title":"Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: impact on clinical counselling","volume":"17","author":"Gross","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1016\/j.kint.2020.06.038","article-title":"Genotype-phenotype correlations influence the response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome","volume":"98","author":"Yamamura","year":"2020","journal-title":"Kidney Int"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1681\/ASN.2018030228","article-title":"Detection of splicing abnormalities and genotype-phenotype correlation in X-linked Alport syndrome","volume":"29","author":"Horinouchi","year":"2018","journal-title":"J Am Soc Nephrol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1203\/PDR.0b013e3181b9b4d3","article-title":"A deep intronic mutation in the SLC12A3 gene leads to Gitelman syndrome","volume":"66","author":"Nozu","year":"2009","journal-title":"Pediatr Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"630","DOI":"10.2215\/CJN.06730810","article-title":"Recurrent deep intronic mutations in the SLC12A3 gene responsible for Gitelman's syndrome","volume":"6","author":"Lo","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.2215\/CJN.04140414","article-title":"X-linked Alport syndrome caused by splicing mutations in COL4A5","volume":"9","author":"Nozu","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"12696","DOI":"10.1038\/s41598-019-48990-9","article-title":"Determination of the pathogenicity of known COL4A5 intronic variants by in vitro splicing assay","volume":"9","author":"Horinouchi","year":"2019","journal-title":"Sci Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nrg1327","article-title":"Genomic variants in exons and introns: identifying the splicing spoilers","volume":"5","author":"Pagani","year":"2004","journal-title":"Nat Rev Genet."},{"key":"B17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S1097-2765(03)00270-3","article-title":"Pre-mRNA splicing: awash in a sea of proteins","volume":"12","author":"Jurica","year":"2003","journal-title":"Mol Cell"},{"key":"B18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/BF00210743","article-title":"The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences","volume":"90","author":"Krawczak","year":"1992","journal-title":"Hum Genet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1086\/302418","article-title":"Splicing defects in the ataxia-telangiectasia gene, ATM: underlying mutations and consequences","volume":"64","author":"Teraoka","year":"1999","journal-title":"Am J Hum Genet."},{"key":"B20","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/hmg\/9.2.237","article-title":"Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1","volume":"9","author":"Ars","year":"2000","journal-title":"Hum Mol Genet."},{"key":"B21","doi-asserted-by":"publisher","first-page":"26580","DOI":"10.1074\/jbc.M212813200","article-title":"Missense, nonsense, and neutral mutations define juxtaposed regulatory elements of splicing in cystic fibrosis transmembrane regulator exon 9","volume":"278","author":"Pagani","year":"2003","journal-title":"J Biol Chem."},{"key":"B22","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ekir.2021.10.012","article-title":"Last nucleotide substitutions of COL4A5 exons cause aberrant splicing","volume":"7","author":"Aoto","year":"2021","journal-title":"Kidney Int Rep"},{"key":"B23","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s10157-015-1197-9","article-title":"X-linked Alport syndrome associated with a synonymous p.Gly292Gly mutation alters the splicing donor site of the type IV collagen alpha chain 5 gene","volume":"20","author":"Fu","year":"2016","journal-title":"Clin Exp Nephrol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e1342","DOI":"10.1002\/mgg3.1342","article-title":"Pathogenic evaluation of synonymous COL4A5 variants in X-linked Alport syndrome using a minigene assay","volume":"8","author":"Horinouchi","year":"2020","journal-title":"Mol Genet Genomic Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1007\/s00439-002-0830-3","article-title":"Unusual deep intronic mutations in the COL4A5 gene cause X linked Alport syndrome","volume":"111","author":"King","year":"2002","journal-title":"Hum Genet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"6414","DOI":"10.1128\/MCB.20.17.6414-6425.2000","article-title":"Multiple splicing defects in an intronic false exon","volume":"20","author":"Sun","year":"2000","journal-title":"Mol Cell Biol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/j.1742-4658.2009.07520.x","article-title":"Alternative splicing: role of pseudoexons in human disease and potential therapeutic strategies","volume":"277","author":"Dhir","year":"2010","journal-title":"FEBS J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s10157-018-1534-x","article-title":"Detection of copy number variations by pair analysis using next-generation sequencing data in inherited kidney diseases","volume":"22","author":"Nagano","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00467-018-3985-4","article-title":"Expert consensus guidelines for the genetic diagnosis of Alport syndrome","volume":"34","author":"Savige","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1681\/ASN.2014010057","article-title":"Human urine-derived renal progenitors for personalized modeling of genetic kidney disorders","volume":"26","author":"Lazzeri","year":"2015","journal-title":"J Am Soc Nephrol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/humu.23364","article-title":"Urine-derived podocytes-lineage cells: a promising tool for precision medicine in Alport Syndrome","volume":"39","author":"Daga","year":"2018","journal-title":"Hum Mutat."},{"key":"B33","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/s10157-020-01876-x","article-title":"Functional analysis of suspected splicing variants in CLCN5 gene in Dent disease 1","volume":"24","author":"Inoue","year":"2020","journal-title":"Clin Exp Nephrol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1887984","DOI":"10.1080\/08880018.2021.1887984","article-title":"Usefulness of functional splicing analysis to confirm precise disease pathogenesis in Diamond-Blackfan anemia caused by intronic variants in RPS19","volume":"2021","author":"Takafuji","year":"2021","journal-title":"Pediatr Hematol Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00439-009-0697-7","article-title":"In vivo and in vitro splicing assay of SLC12A1 in an antenatal salt-losing tubulopathy patient with an intronic mutation","volume":"126","author":"Nozu","year":"2009","journal-title":"Hum Genet."},{"key":"B36","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ejmg.2017.08.001","article-title":"A comparison of splicing assays to detect an intronic variant of the OCRL gene in Lowe syndrome","volume":"60","author":"Nakanishi","year":"2017","journal-title":"Eur J Med Genet."},{"key":"B37","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s12882-017-0774-4","article-title":"An in vitro splicing assay reveals the pathogenicity of a novel intronic variant in ATP6V0A4 for autosomal recessive distal renal tubular acidosis","volume":"18","author":"Yamamura","year":"2017","journal-title":"BMC Nephrol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/s10038-018-0436-9","article-title":"Functional splicing analysis in an infantile case of atypical hemolytic uremic syndrome caused by digenic mutations in C3 and MCP genes","volume":"63","author":"Yamamura","year":"2018","journal-title":"J Hum Genet."},{"key":"B39","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s10038-019-0606-4","article-title":"Molecular assay for an intronic variant in NUP93 that causes steroid resistant nephrotic syndrome","volume":"64","author":"Rossanti","year":"2019","journal-title":"J Hum Genet"},{"key":"B40","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1159\/000484209","article-title":"Detection of a splice site variant in a patient with glomerulopathy and fibronectin deposits","volume":"138","author":"Tsuji","year":"2018","journal-title":"Nephron"},{"key":"B41","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00467-016-3565-4","article-title":"Functional assessment of a novel COL4A5 splice region variant and immunostaining of plucked hair follicles as an alternative method of diagnosis in X-linked Alport syndrome","volume":"32","author":"Malone","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"402","DOI":"10.23876\/j.krcp.20.111","article-title":"Genetic background, recent advances in molecular biology, and development of novel therapy in Alport syndrome","volume":"39","author":"Nozu","year":"2020","journal-title":"Kidney Res Clin Pract"},{"key":"B43","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1053\/j.ajkd.2020.03.026","article-title":"Alport syndrome: achieving early diagnosis and treatment","volume":"77","author":"Kashtan","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s40263-019-00656-w","article-title":"An integrated safety analysis of infants and children with symptomatic spinal muscular atrophy (SMA) treated with nusinersen in seven clinical trials","volume":"33","author":"Darras","year":"2019","journal-title":"CNS Drugs."},{"key":"B47","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","article-title":"Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study","volume":"378","author":"Cirak","year":"2011","journal-title":"Lancet"},{"key":"B48","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, tolerability, and efficacy of viltolarsen in boys with duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1038\/s41467-020-16605-x","article-title":"Development of an exon skipping therapy for X-linked Alport syndrome with truncating variants in COL4A5","volume":"11","author":"Yamamura","year":"2020","journal-title":"Nat Commun."},{"key":"B51","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/1471-2350-9-105","article-title":"Assessment of the feasibility of exon 45-55 multiexon skipping for Duchenne muscular dystrophy","volume":"9","author":"van Vliet","year":"2008","journal-title":"BMC Med Genet."},{"key":"B52","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.stem.2016.01.021","article-title":"A single CRISPR-Cas9 deletion strategy that targets the majority of DMD patients restores dystrophin function in hiPSC-derived muscle cells","volume":"18","author":"Young","year":"2016","journal-title":"Cell Stem Cell"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e0197084","DOI":"10.1371\/journal.pone.0197084","article-title":"Antisense PMO cocktails effectively skip dystrophin exons 45-55 in myotubes transdifferentiated from DMD patient fibroblasts","volume":"13","author":"Lee","year":"2018","journal-title":"PLoS ONE."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1001\/jama.2020.16783","article-title":"Oral drug approved for spinal muscular atrophy","volume":"324","author":"Jaklevic","year":"2020","journal-title":"JAMA"},{"key":"B55","doi-asserted-by":"publisher","first-page":"E4604","DOI":"10.1073\/pnas.1800260115","article-title":"Mechanistic studies of a small-molecule modulator of SMN2 splicing","volume":"115","author":"Wang","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B56","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1203\/PDR.0b013e31822e1825","article-title":"Kinetin improves IKBKAP mRNA splicing in patients with familial dysautonomia","volume":"70","author":"Axelrod","year":"2011","journal-title":"Pediatr Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1073\/pnas.1415525112","article-title":"Rectifier of aberrant mRNA splicing recovers tRNA modification in familial dysautonomia","volume":"112","author":"Yoshida","year":"2015","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.841391\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T08:07:27Z","timestamp":1644307647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.841391\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,8]]},"references-count":57,"alternative-id":["10.3389\/fmed.2022.841391"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.841391","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,8]]},"article-number":"841391"}}